Core Insights - Voya Financial, Inc. (VOYA) reported fourth-quarter 2025 adjusted operating earnings of $1.94 per share, missing the Zacks Consensus Estimate by 8%, but showing a year-over-year increase of 38.5% [1][9] - The earnings growth was driven by higher earnings across all segments, partially offset by increased performance-based compensation accruals in Corporate [1] - The company’s adjusted operating revenues reached $2 billion, reflecting a 5.7% year-over-year increase [2] Financial Performance - Net investment income rose 13.4% year over year to $591 million, while fee income increased by 16.5% to $633 million [2][9] - Premiums totaled $738 million, down 6.5% from the previous year [2] - Total benefits and expenses were $1.9 billion, up 2.7% year over year [2] Segment Analysis - Retirement segment reported pre-tax adjusted operating earnings of $255 million, a 21.4% increase year over year, attributed to acquired business from OneAmerica and strong execution [4] - Employee Benefits segment narrowed its pre-tax adjusted operating loss to $10 million from a loss of $102 million in the prior year, driven by improved underwriting margins [5] - Investment Management posted pre-tax adjusted operating earnings of $72 million, a 9% increase year over year, with net inflows of $1.2 billion [6] Asset Management - As of December 31, 2025, Voya's assets under management and administration totaled $1.1 trillion [3] - Total client assets in the Retirement segment reached $797 billion, up 30% year over year [4] Capital and Debt - Voya Financial ended the quarter with cash and cash equivalents of $1.2 billion, a decrease of 12.2% year over year [8] - Long-term debt was reported at $1.5 billion, down 27.8% from the end of 2024 [10] - The financial leverage ratio improved by 330 basis points year over year to 27% [10] Capital Deployment - The company returned $120 million to shareholders through share repurchases and $44 million through common stock dividends in the reported quarter [11] - As of December 31, 2025, Voya had approximately $0.4 billion in excess capital and a remaining share repurchase authorization of $562 million [11] Full-Year Highlights - For the full year 2025, adjusted operating earnings per share were $8.85, a 22% increase year over year, although it missed the Zacks Consensus Estimate by 1.8% [12] - Adjusted operating revenues for the year increased by 3.3% to $7.7 billion [12]

Key Takeaways IBM beat Q4 2025 earnings and revenue estimates on strong software growth led by hybrid cloud and watsonx AI.Hybrid cloud and AI demand, Red Hat momentum and healthy consulting drove IBM's software performance.Stiff competition, pricing pressure, FX volatility and job cuts remain key risks for IBM's profitability.International Business Machines Corporation (IBM) reported strong fourth-quarter 2025 results, with adjusted earnings and revenues beating the respective Zacks Consensus Estimate. The ...

Core Insights - Mercury Systems (MRCY) reported adjusted earnings of 16 cents per share for Q2 fiscal 2026, exceeding the Zacks Consensus Estimate by 128.6% and significantly up from 7 cents per share in the same quarter last year [1] - Revenues for the second quarter reached $232.87 million, marking a 4.4% year-over-year increase and surpassing the Zacks Consensus Estimate by 12.29% [1] Q2 Details - Total bookings for Q2 fiscal 2026 were $288 million, resulting in a book-to-bill ratio of 1.23 [2] - The company achieved a record backlog of $1.5 billion, which is an 8.8% increase year over year [2] Q2 Operating Details - Adjusted EBITDA for Q2 fiscal 2026 was $30 million, a 36.3% increase from $22 million in Q2 fiscal 2025 [3] - The adjusted EBITDA margin improved to 12.9% year over year [3] - GAAP net loss for the quarter was $15.1 million, with a diluted loss per share of 26 cents, compared to a net loss of $17.6 million and a loss per share of 30 cents in the prior year [3] Balance Sheet & Cash Flow - As of December 26, 2025, cash and cash equivalents were $335 million, up from $304.7 million as of September 26, 2025 [4] - Long-term debt remained unchanged at $591.5 million [4] - Cash flow from operations was $51.6 million, a significant increase from $2.2 million in the previous quarter [4] - Free cash flow for Q2 fiscal 2026 was $45.7 million, compared to negative $4.4 million in Q1 fiscal 2026 [4] Fiscal 2026 Outlook - The company maintains its full-year fiscal 2026 outlook, expecting low single-digit annual revenue growth and an adjusted EBITDA margin approaching the mid-teens [5] - Anticipates positive free cash flow for the year, with Q3 revenues expected to decline year over year, followed by a ramp-up in Q4 [5] - Q3 adjusted EBITDA margin is projected to approach double digits, while Q4 is expected to have the highest adjusted EBITDA margin of the fiscal year [5] Zacks Rank & Stocks to Consider - MRCY currently holds a Zacks Rank 4 (Sell) [6] - Other stocks in the aerospace sector with better rankings include CAE (Rank 2), Innovative Solution (Rank 1), and Bae Systems (Rank 2) [6]

Key Takeaways Bitcoin and Ethereum sold off as a stronger dollar and hawkish Fed expectations pressured crypto ETFs.Liquidity concerns and fewer expected rate cuts limit near-term upside for spot crypto ETFs.While regulation and AI optimism help long term, mining risks and policy uncertainty keep crypto volatile. Bitcoin, the world’s largest cryptocurrency by market value, fell about 12% past week (as of Feb. 1, 2026). At the time of writing, the currency slid below $80, 000, its weakest level since Novembe ...

Core Insights - AbbVie reported quarterly earnings of $2.71 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, and showing an increase from $2.16 per share a year ago, resulting in an earnings surprise of +2.02% [1] - The company achieved revenues of $16.62 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.58% and increasing from $15.1 billion year-over-year [2] Earnings Performance - AbbVie has consistently surpassed consensus EPS estimates over the last four quarters, with the latest earnings surprise being +5.08% compared to the previous quarter's expectation of $1.77 per share [1][2] - The current consensus EPS estimate for the upcoming quarter is $3.12, with projected revenues of $15.2 billion, and for the current fiscal year, the estimate is $14.32 on revenues of $67.28 billion [7] Stock Performance and Outlook - AbbVie shares have underperformed the market, losing about 1.2% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8]

COMPANY ANNOUNCEMENT NO. 08-2026 FLSmidth & Co. A/S 4 February 2026 Copenhagen, Denmark FLSmidth & Co. A/S (FLSmidth) today announces that Toni Laaksonen has been appointed Chief Executive Officer (CEO), effective immediately. Toni joined FLSmidth as Service Business Line President in June 2025. Toni succeeds Mikko Keto, who in November 2025 informed the Board of Directors of his decision to leave the company to pursue an opportunity outside FLSmidth (ref. Company Announcement no. 44-2025). The appointment ...

Zach Dell is the co-founder and CEO of Base Power, a home-battery company that has raised more than $1.3 billion from investors. ...

Full Transcript: Aytu BioPharma Q2 2026 Earnings Callby Benzinga Insights Benzinga Staff WriterFollowArticleFeaturedTickersList12345!!!Aytu BioPharma (NASDAQ:AYTU) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/.The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53322Full Transcri ...

Core Insights - UBS AG has exceeded market expectations with its fourth-quarter earnings report, showcasing strong financial health and strategic growth initiatives [1][5] Financial Performance - UBS reported earnings per share of $0.37, surpassing the estimated $0.25, and revenue of approximately $12.2 billion, exceeding the estimated $9.25 billion [2] - The bank's net profit for the quarter was $1.2 billion, exceeding analysts' expectations of $919 million, despite a decline from the previous quarter's net profit of $2.5 billion [2] - Group revenues for the quarter reached $12.1 billion, aligning with forecasts and showing an increase from $11.6 billion in the same period last year [2] Strategic Initiatives - UBS announced a $3 billion share buyback program, reflecting confidence in its financial stability and future growth prospects [3] Financial Metrics - The common equity tier 1 (CET1) capital ratio stood at 14.4% for the fourth quarter, slightly down from 14.8% in the previous quarter [3] - The price-to-earnings (P/E) ratio is approximately 20.65, while the price-to-sales ratio is about 2.02 [4] - The enterprise value to sales ratio is around 3.96, and the enterprise value to operating cash flow ratio is approximately 68.63 [4] - UBS's earnings yield is about 4.84%, with a debt-to-equity ratio of 4.07, indicating financial leverage [4] - The current ratio of 0.28 may suggest potential liquidity challenges in meeting short-term obligations [4] Conclusion - UBS AG's strong fourth-quarter performance and strategic financial management position it as a strong contender in the global banking sector, with solid growth prospects and a commitment to returning value to shareholders [5]

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, before the market opens. Acadia will also conduct a conference call with institutional investors and analysts on Wednesday, February 25, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the "Investors†section of the website. The webcast of. ...